Suppr超能文献

病例报告:甲泼尼龙冲击疗法联合环孢素A及羟氯喹治疗抗MDA5阳性无肌病性皮肌炎伴快速进展性间质性肺疾病

Case Report: Treatment of Anti-MDA5-Positive Amyopathic Dermatomyositis Accompanied by a Rapidly Progressive Interstitial Lung Diseases With Methylprednisolone Pulse Therapy Combined With Cyclosporine A and Hydroxychloroquine.

作者信息

Zhang Qia-Chun, Liu Min-Ying, Chen Zhi-Xin, Chen Yimin Talia, Lin Chang-Song, Xu Qiang

机构信息

Guangzhou University of Chinese Medicine, Guangzhou, China.

Bao'an Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine, Shenzhen, China.

出版信息

Front Med (Lausanne). 2020 Nov 27;7:610554. doi: 10.3389/fmed.2020.610554. eCollection 2020.

Abstract

Patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive amyopathic dermatomyositis (ADM) often develop rapidly progressive interstitial lung diseases (RP-ILD), with poor treatment success. Many studies have shown that this is the main cause of death in patients with anti-MDA5 antibody-positive ADM. A 37-years-old woman developed a cough, shortness of breath, and a rash on both hands, which resembled Gottron's signs. Upon laboratory examination, the results were as follows: antinuclear antibody (ANA) positive; anti-Ro52 antibody positive; and anti-MDA5 antibody positive. Pulmonary high-resolution CT (HRCT) scan showed pulmonary interstitial inflammatory changes, and mediastinal and subcutaneous emphysema. She was finally diagnosed with anti-MDA5 antibody-positive ADM accompanied by RP-ILD. She was first given high-dose-steroid pulse therapy with methylprednisolone (500 mg per day for 3 days) followed by methylprednisolone (40 mg, daily), cyclosporine A (100 mg, twice per day), and hydroxychloroquine (200 mg, twice per day). Since her discharge from our hospital in March of 2018, she has maintained the methylprednisolone therapy (tapered to 10 mg daily), cyclosporine A (100 mg, twice per day), and hydroxychloroquine (200 mg, twice per day). Pulmonary HRCT scans taken on 4, 9, and 26 months after her discharge from our hospital showed that the interstitial pneumonitis had significantly improved and that mediastinal and subcutaneous emphysema had been gradually absorbed. The patient can now participate in regular work and activities of daily living. The treatment of methylprednisolone pulse therapy combined with cyclosporine A and hydroxychloroquine may be an option for the RP-ILD accompanied by anti-MDA-positive ADM. After the acute phase, this combination therapy strategy is helpful to the disease control of patients.

摘要

抗黑色素瘤分化相关基因5(MDA5)抗体阳性的无肌病性皮肌炎(ADM)患者常迅速发展为进行性间质性肺病(RP - ILD),治疗效果不佳。许多研究表明,这是抗MDA5抗体阳性ADM患者的主要死因。一名37岁女性出现咳嗽、气短,双手出现类似Gottron征的皮疹。实验室检查结果如下:抗核抗体(ANA)阳性;抗Ro52抗体阳性;抗MDA5抗体阳性。肺部高分辨率CT(HRCT)扫描显示肺部间质炎症改变,以及纵隔和皮下气肿。她最终被诊断为抗MDA5抗体阳性ADM伴RP - ILD。她首先接受了大剂量糖皮质激素冲击治疗,静脉滴注甲泼尼龙(每天500 mg,共3天),随后口服甲泼尼龙(40 mg,每日)、环孢素A(100 mg,每日2次)和羟氯喹(200 mg,每日2次)。自2018年3月出院以来,她一直维持甲泼尼龙治疗(逐渐减量至每日10 mg)、环孢素A(100 mg,每日2次)和羟氯喹(200 mg,每日2次)。出院后4个月、9个月和26个月进行的肺部HRCT扫描显示,间质性肺炎明显改善,纵隔和皮下气肿逐渐吸收。患者现在能够参加正常工作和日常生活活动。甲泼尼龙冲击治疗联合环孢素A和羟氯喹治疗可能是抗MDA阳性ADM伴RP - ILD的一种治疗选择。急性期过后,这种联合治疗策略有助于患者疾病的控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0d1/7732655/7500665393bd/fmed-07-610554-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验